<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
TARRYTOWN, N.Y., Nov. 4, 2021 /PRNewswire/ — Third quarter 2021 revenues increased 51% to $3.45 billion versus third quarter 2020 including $804 million attributable to REGEN-COV ® (2) Third quarter 2021 EYLEA® U.S. net sales increased 12% versus third quarter 2020 to $1.47 billion Third quarter 2021 Dupixent® global net sales (3) , which are recorded by Sanofi, increased 55% to $1.66 billion versus third quarter 2020 Third quarter 2021 GAAP diluted EPS was $14.33 and non-GAAP diluted EPS (1) was $15.37 Positive results reported from four Phase 3 Dupixent studies; FDA expanded approval of Dupixent to include children aged 6 to 11 years with asthma Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2021 and provided a business update.
...read full article on PRNewsWire
